Columbia scientists discover surprising link between serotonin and heart valve disease
Recent findings from Columbia University suggest that the mood-regulating chemical serotonin may accelerate the progression of mitral regurgitation in certain patients. The study highlights a potential risk for those using common antidepressants who also possess specific genetic markers.
Columbia University researchers have identified a correlation between serotonin levels and the progression of degenerative mitral regurgitation, a common heart valve condition. The study indicates that the neurotransmitter, typically associated with mood regulation, can influence the structural integrity of heart valves by promoting cellular changes that lead to severe damage.
The research specifically points to patients taking Selective Serotonin Reuptake Inhibitors (SSRIs) who also carry a particular genetic variant. In these individuals, the increased availability of serotonin appears to speed up the thickening of the mitral valve, which may lead to a faster decline in heart function compared to patients without these specific factors.
As a result, these patients may require surgical intervention at a younger age than previously expected. While SSRIs are vital for mental health management, the scientists suggest that genetic screening could eventually help clinicians identify heart patients who might be at higher risk for valve deterioration. This information was sourced from Columbia University Irving Medical Center.
